Form 4: BMY Director Deepak Bhatt Acquires Deferred Share Units

Bristol Myers Squibb Director Deepak Bhatt acquired 3,996.367 Deferred Share Units at $55.05 each, increasing his beneficial ownership to 19,241.818 units.

Summary

• Deepak Bhatt, a Director of Bristol Myers Squibb Co (BMY), acquired 3,996.367 Deferred Share Units.
• The transaction occurred on February 1, 2026.
• Each Deferred Share Unit has a price of $55.05.
• Following this acquisition, Bhatt beneficially owns a total of 19,241.818 Deferred Share Units.
• These units will convert into common stock upon settlement when Bhatt ceases to be a director or at a future specified date.
• The transaction was made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as a director increasing their stake typically indicates confidence in the company's future performance and aligns their interests with shareholders.

Positives

• A Director, Deepak Bhatt, increased his beneficial ownership in the company by acquiring 3,996.367 Deferred Share Units.
• This acquisition, made at $55.05 per unit, aligns the director's interests more closely with those of shareholders.
• The transaction was executed under a Rule 10b5-1(c) plan, indicating a pre-planned acquisition strategy.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

Deferred Share Units will be converted into shares of common stock upon settlement, which occurs when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

Industry Context

StockSavvy.ai notes that insider purchases, particularly by directors, are often interpreted by the market as a signal of confidence in the company's future prospects and valuation. This transaction by a Bristol Myers Squibb director could be viewed positively within the pharmaceutical industry, suggesting internal belief in the company's strategic direction or undervalued stock.

Comparison to Industry Standards

• Insider buying activity, such as this acquisition by a director, is generally seen as a positive indicator across all industries, including pharmaceuticals.
• While specific comparable companies or projects are not detailed in this filing, similar director acquisitions at companies like Pfizer (PFE) or Merck (MRK) would typically be viewed through the same lens of management confidence.
• The acquisition of DSUs, a common form of executive compensation and retention, aligns with standard corporate governance practices for non-employee directors in large-cap pharmaceutical companies.

Related Party Transactions

• The acquisition of Deferred Share Units by Director Deepak Bhatt is an insider transaction, aligning his interests with the company's performance.

Stakeholder Impact

• Shareholders: Increased alignment of a director's interests with shareholders, potentially signaling confidence in the company's future.

Next Steps

• The Deferred Share Units will be converted into common stock upon settlement, which will occur when Deepak Bhatt ceases to be a director or at a future date he previously specified.

Key Dates

Recommendation

A seasoned investor or institution would view a director's acquisition of additional equity, especially through a pre-planned 10b5-1 program, as a strong signal of internal confidence in the company's valuation and future prospects. This insider buying suggests that management believes the stock is a good investment, warranting a 'buy' recommendation.

Keywords

Bristol Myers Squibb, BMY, Deepak Bhatt, Director, Insider Trading, Form 4, Deferred Share Units, Equity Acquisition, 10b5-1 plan